AbCellera Biologics
ABCL
ABCL
183 hedge funds and large institutions have $980M invested in AbCellera Biologics in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 63 increasing their positions, 55 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
10% less funds holding
Funds holding: 203 → 183 (-20)
24% less capital invested
Capital invested by funds: $1.3B → $980M (-$316M)
45% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 40
Holders
183
Holding in Top 10
6
Calls
$13.3M
Puts
$2.2M
Top Buyers
| 1 | +$7M | |
| 2 | +$5.88M | |
| 3 | +$5.2M | |
| 4 |
HF
HRT Financial
New York
|
+$4.19M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.83M |
Top Sellers
| 1 | -$7.38M | |
| 2 | -$5.31M | |
| 3 | -$3.09M | |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
-$2.97M |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$2.06M |